The closing price of Agios Pharmaceuticals Inc (NASDAQ: AGIO) was $30.63 for the day, up 2.30% from the previous closing price of $29.94. In other words, the price has increased by $+0.69 from its previous closing price. On the day, 802779 shares were traded.
Ratios:
Our analysis of AGIO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.99 and its Current Ratio is at 12.27. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
On February 03, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $41.
Goldman Upgraded its Sell to Neutral on November 17, 2022, whereas the target price for the stock was revised from $17 to $32.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 10 ’24 when FOUSE JACQUALYN A sold 7,791 shares for $27.55 per share. The transaction valued at 214,642 led to the insider holds 137,396 shares of the business.
Foster-Cheek Kaye I sold 1,285 shares of AGIO for $40,632 on Mar 07 ’24. The Director now owns 5,524 shares after completing the transaction at $31.62 per share. On Mar 06 ’24, another insider, Foster-Cheek Kaye I, who serves as the Director of the company, sold 4,415 shares for $31.99 each. As a result, the insider received 141,236 and left with 6,809 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGIO now has a Market Capitalization of 1.72B and an Enterprise Value of 1.02B. For the stock, the TTM Price-to-Sale (P/S) ratio is 64.17 while its Price-to-Book (P/B) ratio in mrq is 2.11. Its current Enterprise Value per Revenue stands at 37.89 whereas that against EBITDA is -2.64.
Stock Price History:
Over the past 52 weeks, AGIO has reached a high of $35.50, while it has fallen to a 52-week low of $19.80. The 50-Day Moving Average of the stock is 28.74, while the 200-Day Moving Average is calculated to be 25.42.
Shares Statistics:
AGIO traded an average of 810.98K shares per day over the past three months and 617.49k shares per day over the past ten days. A total of 55.95M shares are outstanding, with a floating share count of 54.74M. Insiders hold about 2.58% of the company’s shares, while institutions hold 106.21% stake in the company. Shares short for AGIO as of Mar 15, 2024 were 6.85M with a Short Ratio of 8.14, compared to 7.65M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 12.19% and a Short% of Float of 12.33%.
Earnings Estimates
The firm’s stock currently is rated by 9 analysts. On average, analysts expect EPS of -$1.64 for the current quarter, with a high estimate of -$1.48 and a low estimate of -$1.78, while EPS last year was -$1.47. The consensus estimate for the next quarter is -$1.66, with high estimates of -$1.46 and low estimates of -$1.82.
Analysts are recommending an EPS of between -$3.03 and -$7.13 for the fiscal current year, implying an average EPS of -$5.8. EPS for the following year is -$5.89, with 9 analysts recommending between -$3.14 and -$8.8.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $12.92M to a low estimate of $7.1M. As of the current estimate, Agios Pharmaceuticals Inc’s year-ago sales were $5.61M, an estimated increase of 54.90% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $9.51M, an increase of 47.20% less than the figure of $54.90% in the same quarter last year. There is a high estimate of $14.91M for the next quarter, whereas the lowest estimate is $7.5M.
A total of 8 analysts have provided revenue estimates for AGIO’s current fiscal year. The highest revenue estimate was $62.66M, while the lowest revenue estimate was $31M, resulting in an average revenue estimate of $42.65M. In the same quarter a year ago, actual revenue was $26.82M, up 59.00% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $113.7M in the next fiscal year. The high estimate is $273M and the low estimate is $65.4M. The average revenue growth estimate for next year is up 166.60% from the average revenue estimate for this year.
